These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells. Villa NY; Bais S; Chan WM; Meacham AM; Wise E; Rahman MM; Moreb JS; Rosenau EH; Wingard JR; McFadden G; Cogle CR Cytotherapy; 2016 Mar; 18(3):465-80. PubMed ID: 26857235 [TBL] [Abstract][Full Text] [Related]
5. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Villa NY; Wasserfall CH; Meacham AM; Wise E; Chan W; Wingard JR; McFadden G; Cogle CR Blood; 2015 Jun; 125(24):3778-88. PubMed ID: 25904246 [TBL] [Abstract][Full Text] [Related]
6. Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer. Villa NY; Franco LS; McFadden G Methods Mol Biol; 2020; 2058():95-110. PubMed ID: 31486033 [TBL] [Abstract][Full Text] [Related]
7. Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease. Villa NY; McFadden G Curr Pathobiol Rep; 2018; 6(4):247-263. PubMed ID: 30595970 [TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Madlambayan GJ; Bartee E; Kim M; Rahman MM; Meacham A; Scott EW; McFadden G; Cogle CR Leuk Res; 2012 May; 36(5):619-24. PubMed ID: 22341701 [TBL] [Abstract][Full Text] [Related]
9. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Weng M; Gong W; Ma M; Chu B; Qin Y; Zhang M; Lun X; McFadden G; Forsyth P; Yang Y; Quan Z Mol Cancer; 2014 Apr; 13():82. PubMed ID: 24725816 [TBL] [Abstract][Full Text] [Related]
10. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818 [TBL] [Abstract][Full Text] [Related]
11. Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma. Christie JD; Appel N; Canter H; Achi JG; Elliott NM; de Matos AL; Franco L; Kilbourne J; Lowe K; Rahman MM; Villa NY; Carmen J; Luna E; Blattman J; McFadden G Mol Ther Oncolytics; 2021 Sep; 22():539-554. PubMed ID: 34553039 [TBL] [Abstract][Full Text] [Related]
12. Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model. Nounamo B; Liem J; Cannon M; Liu J Mol Ther Oncolytics; 2017 Sep; 6():90-99. PubMed ID: 28875159 [TBL] [Abstract][Full Text] [Related]
13. Dual-Armed Oncolytic Myxoma Virus Encoding IFN-γ and CD47 Promotes Lymphocyte Infiltration and Tumor Suppression of Syngeneic Murine Melanoma. Woo JK; Kim TG; Im NY; Son KY; Cho M; Jeong YJ; Hong JI; Kang B; Enkhtaivan G; Cho NH; Alain T; Park DG; Lee YS Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835397 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic myxoma virus: the path to clinic. Chan WM; Rahman MM; McFadden G Vaccine; 2013 Sep; 31(39):4252-8. PubMed ID: 23726825 [TBL] [Abstract][Full Text] [Related]
15. Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Correa RJ; Komar M; Tong JG; Sivapragasam M; Rahman MM; McFadden G; Dimattia GE; Shepherd TG Gynecol Oncol; 2012 May; 125(2):441-50. PubMed ID: 22306204 [TBL] [Abstract][Full Text] [Related]
16. Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma. Christie JD; Appel N; Zhang L; Lowe K; Kilbourne J; Daggett-Vondras J; Elliott N; Lucas AR; Blattman JN; Rahman MM; McFadden G Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053501 [TBL] [Abstract][Full Text] [Related]
17. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma. Pisklakova A; McKenzie B; Zemp F; Lun X; Kenchappa RS; Etame AB; Rahman MM; Reilly K; Pilon-Thomas S; McFadden G; Kurz E; Forsyth PA Neuro Oncol; 2016 Aug; 18(8):1088-1098. PubMed ID: 26962017 [TBL] [Abstract][Full Text] [Related]
19. Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma. Jazowiecka-Rakus J; Hadrys A; Rahman MM; McFadden G; Fidyk W; Chmielik E; Pazdzior M; Grajek M; Kozik V; Sochanik A Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808692 [TBL] [Abstract][Full Text] [Related]
20. Targeting gallbladder carcinoma: bone marrow-derived stem cells as therapeutic delivery vehicles of myxoma virus. Weng M; Zhang M; Qin Y; Gong W; Tang Z; Quan Z; Wu K Chin Med J (Engl); 2014; 127(12):2350-6. PubMed ID: 24931255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]